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RetrovirusXenotropic murine leukemia virus-related virus (XMRV) is a novel retrovirus, related to murine leukemia
virus (MLV), that has been implicated in human disease. If XMRV is indeed able to replicate in humans, then
one might predict that XMRV would have developed resistance to human innate antiviral resistance factors
such as APOBEC3G (hA3G). In fact, we observed that XMRV andMLV are both highly sensitive to inhibition by
hA3G and equally resistant to inhibition by murine APOBEC3. While several human prostate cancer cell lines
were found to lack hA3G, stable expression of physiological levels of hA3G rendered these cells refractory to
XMRV replication. Few human tissues fail to express hA3G, and we therefore hypothesize that XMRV
replicates in one or more hA3G-negative reservoir tissues and/or that human XMRV infections are likely to be
rare and potentially of zoonotic origin.netics and Microbiology, Duke
0, USA. Fax: +1 919 681 8979.
.
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Xenotropic murine leukemia virus-related virus (XMRV) is a
recently discovered γ-retrovirus that is closely related to murine
leukemia virus (MLV) (Urisman et al., 2006). However, unlike
canonical MLV isolates, XMRV encodes a xenotropic envelope protein
that allows it to infect most human cells, but not mouse cells, in
culture. XMRV was ﬁrst identiﬁed in prostate tumors in a cohort of
patients lacking a functional RNaseL gene (Urisman et al., 2006).
Subsequent work has produced variable results, with some groups
conﬁrming the presence of XMRV in a signiﬁcant percentage of
prostate cancer patients, while other groups have failed to detect
XMRV in prostate tumors (reviewed by (Silverman et al., 2010).
Clearly, however, XMRV is able to replicate effectively in some human
prostate cancer cell lines in culture (Rodriguez and Goff, 2010b), and
at least one prostate cancer cell line, 22RV1, is constitutively infected
with XMRV and produces infectious XMRV virions (Knouf et al., 2009;
Paprotka et al., 2010).
Recently, it has also been reported that XMRV is detectable in a
high proportion of patients suffering from chronic fatigue syndrome
(CFS) (Lombardi et al., 2009). This paper also reported that XMRV
could replicate in human peripheral bloodmononuclear cells (PBMCs)
and that up to 3.7% of healthy individuals are naturally infected with
XMRV. Given the above proposed disease associations, and the knowntendency of γ-retroviruses to cause cancer and neurological diseases
in animals (Li et al., 2009; Peterson et al., 2001), it is clearly important
to determine whether XMRV is an authentic human virus and, if so,
how it maintains itself in vivo and spreads in the human population.
Research over the last decade has revealed that mammalian
species, including humans, encode an array of innate antiretroviral
resistance factors (Malim and Emerman, 2008). The ﬁrst human
antiretroviral protein to be identiﬁed was human APOBEC3G (hA3G),
which potently inhibits the infectivity of HIV-1 variants lacking a
functional vif gene (HIV-1ΔVif) (Sheehy et al., 2002). In contrast,
wild-type HIV-1 is highly resistant to hA3G due to the ability of the
viral Vif protein to bind hA3G and induce its degradation (reviewed by
(Albin and Harris, 2010; Cullen, 2006; Malim, 2009). In the absence of
Vif, hA3G is efﬁciently packaged into progeny HIV-1 virions and then
blocks the formation of functional HIV-1 proviruses in newly infected
cells. A key aspect of the antiviral activity of hA3G is its ability to
function as an ssDNA-speciﬁc deoxycytidine deaminase. In the newly
infected cell, hA3G induces hypermutation of HIV-1 proviruses by
editing dC to dU in the proviral minus strand. During second strand
synthesis, dU is recognized by the reverse transcriptase (RT) enzyme
as dT, resulting in a mutation from G to A on the proviral plus strand.
Editing by hA3G both destabilizes the HIV-1 proviral intermediate and
introduces deleterious mutations, including stop codons, into viral
genes (Albin and Harris, 2010; Cullen, 2006; Malim, 2009).
While hA3G is likely the most functionally signiﬁcant antiviral
APOBEC3 protein, it is not the only one. In fact, humans encode seven
APOBEC3 proteins, named APOBEC3A (hA3A), hA3B, hA3C, hA3D,
hA3F, hA3G, and hA3H, that show various abilities to block retroviral
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et al., 2006; Jarmuz et al., 2002). Another important APOBEC3 variant,
in terms of inhibiting retroviral infectivity, is hA3F (Bishop et al.,
2004; Liddament et al., 2004; Wiegand et al., 2004; Zennou and
Bieniasz, 2006). Like hA3G, hA3F is widely expressed, has the ability to
inhibit HIV-1ΔVif infectivity and is degraded by HIV-1 Vif. One
interesting difference between hA3G and hA3F is that the former
strongly prefers to edit dC residues present in the sequence 5′-CC*-3′
(where the asterisk indicates the edited residue), while hA3F prefers
to edit 5′-TC*-3′.
While much of the original work of APOBEC3 protein function
focused on HIV-1, these proteins are capable of inhibiting the
replication of a wide variety of retroviruses and all mammalian
species encode at least one APOBEC3 protein (Albin and Harris, 2010;
Cullen, 2006). Mice, for example, encode a single APOBEC3 protein
(mA3) that potently inhibits the activity of not only HIV-1ΔVif but
also wild-type HIV-1 (Abudu et al., 2006; Doehle et al., 2005b). In
contrast, mA3 is a weak inhibitor of MLV infectivity, although hA3G
inhibits MLV very effectively. In fact, it is generally true that
retroviruses are largely, but not totally, resistant to inhibition by the
APOBEC3 proteins that are expressed in the relevant target tissues in
their normal host species but often highly susceptible to inhibition by
APOBEC3 proteins expressed in heterologous species (Cullen, 2006).
From this perspective, we were therefore interested in whether
XMRV, which is closely related to MLV, would differ from MLV in
being able to replicate effectively in the presence of human APOBEC3
proteins, as would be predicted if it is indeed able to productively
infect human PBMCs (Lombardi et al., 2009). Alternatively, XMRV
might share the high susceptibility of MLV to inhibition by hA3G, in
which case one would predict that XMRV would only be able to
replicate in human cells lacking hA3G expression. Here, we show that
this latter model is correct, i.e., that prostate cancer cells permissive
for XMRV replication are unusual in lacking detectable hA3G
expression and that engineering prostate cancer cells to express
physiologically relevant levels of hA3G blocks XMRV replication and
results in extensive editing of XMRV reverse transcripts. These data
conﬁrm and extend recent reports documenting that XMRV is
sensitive to inhibition by hA3G (Groom et al., 2010; Paprotka et al.,Fig. 1. Sensitivity of XMRV to inhibition by selected APOBEC3 proteins. A) 293T cells were tr
well as plasmids expressing the HIV-1 Gag and Pol proteins, the VSV G glycoprotein and the i
and used to infect naïve 293T cells. Induced luciferase levels were assayed ~44 h later (upper
irrelevant HA-tagged protein, β-arrestin, with SD indicated. The producer 293T cells were lys
HIV-1 capsid expression (lower panel). B) Similar to panel A, except that the HIV-1-based pla
Pol expression plasmid. The lower panel was generated using an MLV capsid-speciﬁc goat
substituted for theMLV Gag-Pol expression vector. As previously reported (Rodriguez and Go
capsid antiserum.2010; Stieler and Fischer, 2010) and argue that replication of XMRV in
humans likely only occurs in a limited set of speciﬁc tissues that lack
detectable hA3G expression.
Results
MLV and XMRV show a similar pattern of susceptibility to APOBEC3
proteins
As an initial test of the ability of XMRV to withstand inhibition by
the human APOBEC3 proteins hA3A, hA3B, hA3F and hA3G, as well as
the single murine APOBEC3 protein mA3, we performed a single-cycle
infectivity assay in 293T cells, as previously described (Doehle et al.,
2005a,b; Wiegand et al., 2004). In this assay, 293T cells are co-
transfected with an HIV-1 or MLV-based indicator construct, together
with a plasmid expressing the HIV-1, MLV or XMRV Gag and Pol
proteins, with a vector expressing the VSV glycoprotein (G) and
ﬁnally, with a vector expressing one of the above APOBEC3 proteins.
The level of APOBEC3 expression vector that was co-transfected was
limited to 125 ng, a level chosen because in our hands it permits
efﬁcient inhibition of an HIV-1 proviral vector lacking Vif (HIV-1ΔVif)
by hA3G but does not inhibit an HIV-1 provirus that retains a wild-
type vif gene (Wiegand et al., 2004).
As shown in Fig. 1A, and as previously reported (Doehle et al.,
2005a,b; Wiegand et al., 2004), the infectivity of the HIV-1ΔVif
provirus is potently inhibited by hA3B, hA3F, hA3G and mA3 but
essentially unaffected by hA3A expression. In contrast, none of the
APOBEC3 proteins tested had any effect on HIV-1 Gag protein
production, as expected (Fig. 1A, lower panel). Analysis of the effect
of this same panel of APOBEC3 proteins on MLV infectivity (Fig. 1B)
resulted in the detection of strong inhibition of MLV infectivity by
hA3B and hA3G, but no inhibition by mA3, hA3A or hA3F, as also
previously reported (Doehle et al., 2005b). Again, this inhibition did
not correlate with any effect on MLV Gag protein production (Fig. 1B,
lower panel). Finally, analysis of the effect of APOBEC3 proteins on the
infectivity of virions produced using the XMRV Gag and Pol proteins
(Fig. 1C) gave results that were indistinguishable from what was
observed with MLV Gag and Pol, i.e., potent inhibition by hA3B andansfected with a plasmid encoding a Vif-deﬁcient HIV-1 luciferase expression vector as
ndicated APOBEC3 protein. Virus supernatants were harvested at 48 h post-transfection
panel). Data are given relative to cells transfected with a control plasmid expressing an
ed and used forWestern blots analyzing APOBEC3 protein expression (middle panel) or
smids were substituted with anMLV-based luciferase indicator vector and anMLV Gag-
antiserum. C) Similar to panel B, except that an XMRV Gag-Pol expression vector was
ff, 2010a), the XMRV capsid protein is recognized by the same goat polyclonal anti-MLV
Fig. 2. MLV and XMRV show a similar pattern of sensitivity to APOBEC3 proteins. This
experiment was performed as described in Fig. 1 except that variable levels of
the pcDNA3/hA3G and pcDNA3/mA3 expression vectors, shown in micrograms, were
co-transfected into 293T cells. DNA levels were kept constant by varying the levels of a
co-transfected blank pcDNA3 plasmid. Assays were performed in triplicate with SD
indicated. The lower panels are APOBEC3 Western blots performed using extracts
derived from the producer 293T cells.
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effect on XMRV Gag protein expression was noted (Fig. 1C, lower
panel).
The experiments described in Fig. 1 measure the infectivity of
HIV-1, MLV and XMRV virions pseudotyped with VSV G. To address
whether XMRV virions bearing the XMRV Env protein would behave
any differently, we performed experiments similar to those described in
Fig. 1, but now examined a range of levels of expression of hA3G ormA3
and substituted an XMRV Env expression vector for the VSV G
expression vector. As shown in Fig. 2, we observed that both XMRV
andMLV virions bearing XMRV Envwere resistant to inhibition bymA3
over a wide range of mA3 expression levels. In contrast, both MLV and
XMRV showed a high and equivalent degree of sensitivity to inhibition
by hA3G over the same range of protein expression levels.
The experiments described in Fig. 2 were performed by packaging
proviral indicator vectors in 293T cells co-transfected with either MLVFig. 3. hA3G, but not mA3, inhibits the infectivity of XMRV viruses produced in prostate canc
was co-transfected with the indicated levels of the APOBEC3 expression plasmids pcDNA3
vector pFB-Luc. At 40 h post-transfection, the media were changed and 8 h later harvested, ﬁ
later (upper panels). Data are shown relative to a blank vector control. Assays were performe
for Western blots with an anti-HA monoclonal antibody (lower panels).or XMRV-based Gag and Pol expression vectors and an XMRV Env
expression vector. To extend these studies to a physiologically
relevant target cell type, we next co-transfected the human prostate
cancer cell line 22RV1, which is naturally infected with XMRV and
produces substantial levels of infectious XMRV virions (Knouf et al.,
2009), with the luciferase-based retroviral indicator vector pFB-Luc
and increasing levels of either an hA3G or mA3 expression plasmid. In
this experiment, therefore, pFB-Luc transcripts would be packaged by
endogenous XMRV-derived viral proteins. As shown in Fig. 3, we
again saw substantial inhibition of viral infectivity by the hA3G
protein but failed to see any inhibition upon expression of comparable
levels of mA3. This experiment demonstrates that XMRV does not
encode an inhibitor of hA3G activity that is functional in prostate
cancer cell lines naturally infected by XMRV, a hypothesis recently
proposed by Groom et al. (2010).
Several human prostate cancer cell lines express undetectable levels
of hA3G
To address whether the reported ability of human prostate cancer
cell lines to support XMRV replication (Rodriguez and Goff, 2010b) is
dependenton their lackof hA3Gexpression,weengineered theXMRV+
prostate cancer cell line 22RV1and theXMRV-negative prostate cell line
LNCaP to stably express hA3G by transduction with a lentiviral
expression vector. As shown in Fig. 4A, the resultant polyclonal
LNCaP/hA3G and 22RV1/hA3G cell lines expressed levels of hA3G that
were closely comparable to the levels of endogenous hA3G observed in
the human T-cell lines CEM and H9. As shown in Fig. 4B, we observed
that the parental LNCaP cells are permissive for XMRV replication, as
also previously reported, but observed that the LNCaP/hA3G cells were
entirely unable to support a spreading XMRV infection. To conﬁrm that
this inhibition correlated with the editing of XMRV reverse transcripts
by hA3G, we used endogenous XMRVvirions, recovered from either the
parental 22RV1 cell line or its 22RV1/hA3G derivative, to infect wild-
type LNCaP cells. We then recovered newly generated XMRV proviral
DNA by PCR and subjected the resultant clones to DNA sequencing, as
previously described (Wiegand et al., 2004). As shown in Fig. 5, we
observed 65 G to A mutations, out of 9900 bases sequenced, in XMRV
proviral DNA derived from LNCaP cells infected with XMRV virions
produced in the 22RV1/hA3G cells. Consistent with these mutations
being due to editing by hA3G, we observed that 64 out of 65 mutations
were in the sequence context 5′-GG-3′, consistent with the knowner cells. In this experiment, the naturally XMRV-infected prostate cancer cell line 22RV1
/hA3G or pcDNA3/mA3, given in micrograms, and the retroviral luciferase expression
ltered and used to infect naïve 293T cells. Induced luciferase levels were analyzed ~48 h
d in triplicate with SD indicated. The producer 22RV1 cells were also harvested and used
Fig. 4. hA3G expression in prostate cancer cell lines and T-cell lymphoma cell lines.
A) This Western blot analyzes the level of hA3G expression in the hA3G-negative cell
lines CEM-SS and 293T, the naturally hA3G-positive T-cell lines CEM and H9 and also in
the parental prostate cancer cell lines 22RV1, DU145 and LNCaP. The polyclonal 22RV1/
hA3G and LNCaP/hA3G cell lines were derived by lentiviral vector transduction.
Endogenous β-actin was used as a loading control. B) The parental LNCaP cell line and a
transduced derivative expressing physiological levels of hA3G (panel A) were infected
with XMRV virions produced by the wild-type prostate cancer cell line 22RV1. At 2 days
post-infection, the cells were split and supernatant RT levels monitored from day 3 to
day 6 post-infection. RT activity is given in arbitrary units, average of three experiments
with SD indicated.
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(Bishop et al., 2004; Liddament et al., 2004; Wiegand et al., 2004).
Analysis of XMRV virions derived from the parental 22RV1 cell line
produced an initially confusing result, in thatwe also observed39 G toA
mutations in these cells (Fig. 5). Further analysis revealed that all of
these mutations were present in only two of the twenty-two 450-bp
XMRV gag sequences analyzed. Analysis of these 39mutations revealed
that 28 of these G to Amutations changed a 5′-GA-3′ sequence to 5′-AA-
3′, 8 changed 5′-GG-3′ to 5′-AG-3′ and 3 changed 5′-GC-3′ to 5′-AC-3′,
i.e., the G residue sequences edited in these XMRV sequences are
predominantly (31 out of 39) not located in the consensus 5′-GG-3′A B 22RV1/hA3G22RV1
G A T C
G - 65 0 0
G A T C
G - 39 0 0
A 1 - 0 0
T 0 0 - 0
A 2 - 0 0
T 0 0 - 1
C 0 0 0 -C 0 0 0 -
Fig. 5. Editing of XMRV proviruses derived from virions produced by 22RV1 and 22RV1/
hA3G cells. XMRV virions derived from the parental 22RV1 cell line (A) or from 22RV1
cells engineered to express hA3G (B), as described in Fig. 4A, were used to infect wild-
type LNCaP cells. At 48 h post-infection, total DNA was harvested and a 450 bp segment
of the XMRV gag gene isolated by PCR and cloned. Twenty-two clones were then
sequenced from each infection (9900 bp×2) to reveal the mutations described in this
ﬁgure.editing sequence favored by hA3G and instead are predominantly in the
sequence 5′-GA-3′ favored by hA3F and some other human APOBEC3
proteins (Bishop et al., 2004; Liddament et al., 2004; Wiegand et al.,
2004). One possible explanation for this phenomenon is that 22RV1
expresses endogenous hA3F and that, on rare occasions, this can
package into XMRV virions and induce editing of reverse transcripts.
However, as hA3F is not able to effectively inhibit XMRV infectivity
(Fig. 1C), we consider this unlikely. Moreover, wewere able to use qRT-
PCR analysis to conﬁrm the previous report (Paprotka et al., 2010) that
22RV1 cells are essentially negative for hA3F mRNA (data not shown).
We note that it has previously been reported that the genome of 22RV1
cells contains ≥10 integrated XMRV proviruses and that at least one of
these XMRV proviruses have been heavily edited, primarily at 5′-GA-3′
dinucleotides, by an APOBEC3-like activity (Paprotka et al., 2010). We
therefore hypothesize that the two XMRV sequences we recovered,
using virus derived from wild-type 22RV1 cells, that were edited were
likely transcribed in an edited form in the 22RV1 cells and not edited de
novo upon infection of the LNCaP cells used.
Discussion
In general, the data presented in this manuscript conﬁrm three
recently published reports (Groom et al., 2010; Paprotka et al., 2010;
Stieler and Fischer, 2010) showing that XMRV, like MLV, is highly
sensitive to inhibition by hA3G. However, this work extends these
earlier studies by documenting that expression of physiological levels
of hA3G in human prostate cancer cell lines results in both inhibition
of XMRV replication (Fig. 4) and editing of XMRV reverse transcripts
(Fig. 5). In contrast, previous efforts have been conﬁned to analyzing
the effect of overexpression of APOBEC3 proteins in 293T cells on
XMRV infectivity, as also shown here in Fig. 1. Moreover, our data
disagree with these three earlier publications (Groom et al., 2010;
Paprotka et al., 2010; Stieler and Fischer, 2010) in that we do not see
any evidence that XMRV differs from MLV in being more sensitive to
inhibition by mA3. Rather, in our hands MLV and XMRV behave
indistinguishably in terms of their marked sensitivity to inhibition by
hA3G and their clear resistance to inhibition by either mA3 or hA3F
(Figs. 1 and 2). Importantly, our data therefore argue against the idea
that XMRV differs from MLV in having evolved the ability to counter
inhibition of viral replication by physiological levels of hA3G (Fig. 4B).
XMRV, like MLV, is therefore different from bona ﬁde human
retroviruses, such as HIV-1 and human T-cell leukemia virus type I,
which can both replicate effectively in the presence of physiological
levels of hA3G (Derse et al., 2007; Sheehy et al., 2002). This suggests
that XMRV has either only recently crossed over into the human
population, presumably from a feral murine host, or that XMRV
infections of humans are largely or entirely zoonotic, i.e., that human-
to-human transmission of XMRV is rare. Once XMRV infection of a
human has occurred, our data strongly suggest that this infection
would be conﬁned to the rare tissues that lack hA3G expression,
potentially including the prostate, or at least prostate cancer cells,
while the far more common cells and tissues that express hA3G,
including PBMCs, would be non-permissive for XMRV (Koning et al.,
2009; Refsland et al., 2010). It will therefore be of interest to analyze
whether XMRV proviral DNA recovered from humans shows evidence
of editing by hA3G and to identify the hA3G-negative reservoir(s) of
XMRV-producing human cells in vivo, if these indeed exist.
Materials and methods
Molecular clones
The pcDNA3-based APOBEC3 expression plasmids pcDNA3/hA3A,
pcDNA3/hA3B, pcDNA3/hA3F, pcDNA3/hA3G and pcDNA3/mA3, and
the control plasmid pcDNA3/βArr, have been described (Doehle et al.,
2005a,b; Wiegand et al., 2004). Each of these plasmids encodes the
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previously described are pNL-HXB-LucΔVif, encoding a Vif-deﬁcient
HIV-1 provirus encoding ﬁreﬂy luciferase (Wiegand et al., 2004), and
pTG5349, which encodes the Moloney MLV Gag and Pol proteins
(Negre et al., 2000). The MLV-based luciferase expression vector pFB-
Luc was obtained from Stratagene. pHIT/G is a previously described
VSV G expression plasmid (Wiegand et al., 2004).
Newly generated expression vectors include pTRIPZ-hA3G, which
contains the full-length hA3G open reading frame inserted between
the AgeI and MluI sites present in the doxycycline-inducible lentiviral
expression vector pTRIPZ (Open Biosystems). Also novel are expres-
sion vectors for the XMRV gag/pol and env genes. To generate pCAG/
XGP, genomic DNA from 22RV1 cells was used as a template to
amplify XMRV gag/pol sequences (5.2 kb) with oligonucleotides 5′-
ATTGAATTCGCCACCATGGGACAGACCGTAACTACCCCTCTGAG-3′ and
5′-ATTAATGCGGCCGCTCAGGGGGCCCCACGGGTTAATCTTATC-3′ as
primers. The PCR product was digested with EcoRI/NotI, and inserted
into the pCAGGS expression vector. The resulting Gag/Pol protein
sequence differs at a single amino-acid residue (V60I) from the
prototype VP62 XMRV Gag/Pol sequence (Urisman et al., 2006). To
generate pCAG/XE oligonucleotides 5′-ATTAATGGCGGCCGCGCCAC-
CATGGAAAGTCCAGCGTTCTCAAAACCCC-3′ and 5′-ATTAATGC-
GGCCGCTTATTCACGTGATTCCACTTCTTCTGG-3′ were used to amplify
the XMRV env sequence (1.9 kb) from the same source and the
resulting PCR product was digested with NotI, and inserted into
pCAGGS. The Env protein expressed by pCAG/XE is identical to that
encoded by the VP42 variant of XMRV (Urisman et al., 2006).
Cell culture and transfection
293T, CEM, CEM-SS and H9 cells were maintained as previously
described (Sheehy et al., 2002;Wiegand et al., 2004). LNCaP cells (ATCC
catalog no. CRL-1740) and 22RV1 cells (ATCC catalog no. CRL-2505)
were maintained in RPMI media supplemented with 10% fetal calf
serum (FCS), 10 mMHepes, 1 mM sodium pyruvate and 4.5 g/l glucose.
DU145 cells (ATCC catalog no. HTB-81) were maintained in Eagle's
minimumessentialmediumsupplementedwith10% FCS, 1 mMsodium
pyruvate and non-essential amino acids.
Single cycle assays to measure the effect of APOBEC3 proteins on
retroviral infectivity were performed essentially as previously
described (Wiegand et al., 2004). Brieﬂy, ~3×105 293T cells were
transfected either with 2 μg of the HIV-1ΔVif expression vector pNL-
HXB-LucΔVif, or with 1 μg of pTG5349 and 1 μg of pFB-Luc, or with
1 μg of pCAG/XGP and 1 μg of pFB-Luc. The cells were also co-
transfected with 875 ng of pcDNA3, 125 ng of an APOBEC3 expression
plasmid, or equivalent control plasmid, and 20 ng of pHIT/G. At ~48 h
post-transfection, the supernatant media were harvested, ﬁltered and
used to infect naïve 293T cells. Induced luciferase activity was
measured ~44 h post-infection. In experiments where levels of the
co-transfected APOBEC3 plasmid were varied, the total level of
transfected DNA was maintained by compensatory changes in the
level of the co-transfected pcDNA3 blank vector. In some experiments,
the pHIT/G plasmid was omitted and substituted with the XMRV Env
expression plasmid pCAG/XE.
Infectious lentivirus vector particles were produced by transfec-
tion of 2×106 293T cells with 12 μg of pTRIPZ-hA3G, 8 μg of the HIV-1
packaging plasmid pCMV-ΔR8.74 (Dull et al., 1998) and 200 ng of a
VSV G expression plasmid. At 48 h post-infection, the supernatant
media were harvested, ﬁltered and used to infect LNCaP or 22RV1
cells. At 48 h post-infection, the cells were selected with 1 μg/ml of
puromycin for 1 week to kill non-transduced cells. hA3G expression
was then induced by culture in 1 μg/ml doxycycline for 40 h, at which
point the cells were harvested and used for Western blot analyses. In
the case of the 22RV1 or 22RV1/hA3G cells used for virus production,
the supernatant media were replaced at 40 h after doxycycline
addition with fresh media also containing doxycycline. Eight hourslater, the supernatant media were harvested and used to infect naïve
LNCaP cells.
Analysis of XMRV editing
To analyze editing of XMRV transcript in culture, LNCaP cells were
infected with viral supernatants derived from the parental 22RV1 or
transduced 22RV1/hA3G cell line, as described above. At 48 h post-
infection, total DNA was harvested from the infected cells and a 450-
bp segment of the XMRV gag gene was PCR-ampliﬁed and cloned.
Twenty-two independent clones were then sequenced to detect any
APOBEC3-induced mutations.
RT activity assay
Supernatant medium from 22RV1 cells, which produce infectious
XMRV, was ﬁltered and then used to infect either the parental LNCaP
cell line or LNCaP/hA3G cells which had been pre-incubated for 48 h
with 1 μg/ml doxycycline. LNCaP cells were also maintained in
doxycycline for the duration of the experiment. After 2 days, the
cells were split and supernatant media samples then collected at days
3, 4, 5 and 6 post-infection. RT activity was assayed as previously
described (Telesnitsky et al., 1995). Incorporated radioactivity was
quantiﬁed using a Typhoon 9200 Variable Mode Imager and
ImageQuant software (GE Healthcare Life Sciences).
Western blot analysis
Western blots were performed as previously described (Wiegand
et al., 2004). The antibodies used were a mouse monoclonal anti-HA
epitope antibody (Covance, #MMS-101P), a mousemonocolonal anti-
β-actin antibody (Santa Cruz Biotech #SC-47778), a mouse monoclo-
nal anti-HIV-1 p24 capsid protein antibody (183-H12-5C, AIDS
reagent program #3537) (Chesebro et al., 1992), a goat polyclonal
anti-MLV capsid antiserum (a gift of Stephen Goff) (Rodriguez and
Goff, 2010b) and a human hA3G-speciﬁc rabbit polyclonal antiserum
(anti-ApoC17, AIDS reagent program #10082) (Kao et al., 2004).
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